| I-32 Christian Bartels Getting a better description of treatment effects for time to event data using PKPD modelling Wednesday 09:50-11:15 |
| I-37 Linnea Bergenholm Predicting plasma and liver exposure in humans with a pharmacokinetic model for a GalNAc3-conjugated antisense oligonucleotide using sparse monkey data Wednesday 09:50-11:15 |
| I-50 Marion Bouillon-Pichault Model-based meta-analysis of efficacy and safety of anti-PD1 compounds in melanoma Wednesday 09:50-11:15 |
| I-63 Blesson Chacko Why patients may not benefit from effective oncology drugs Wednesday 09:50-11:15 |
| I-68 Estelle Chasseloup Use of mixture models in pharmacometric model-based analysis of confirmatory trials: part II – control of the type I error with real placebo data Wednesday 09:50-11:15 |
| I-89 Richard Dimelow PK Precision Estimation to support the Design of a Pediatric Study of Belimumab Administered Subcutaneously Wednesday 09:50-11:15 |
| II-13 Hyun A Lee A mechanism-based pharmacokinetic/pharmacodynamic model to evaluate the mutual relationships between YH4808, a novel K+-competitive acid blocker, and intragastric pH in humans Wednesday 15:10-16:40 |
| II-34 Paolo Magni Artificial intelligence and machine learning: just a hype or a new opportunity for pharmacometrics? Wednesday 15:10-16:40 |
| II-48 Robin Michelet A workflow for application of the general pharmacodynamic interaction model on high-throughput combinatorial data in order to identify, quantify and characterise drug combinations that can overcome multi-drug-resistance Wednesday 15:10-16:40 |
| II-59 Bernard Ngara A Semi-mechanistic population pharmacokinetic model quantifying hair concentrations of ritonavir-boosted atazanavir. A study of HIV infected Zimbabweans adolescents. Wednesday 15:10-16:40 |
| II-61 Laura Zwep Hierarchical group LASSO with random effects: identification of high-dimensional omics-drug interactions predictive of treatment response in patient-derived tumor growth data Wednesday 15:10-16:40 |
| II-87 Javier Reig-López Validation of a Semi-mechanistic model with first-pass metabolism, two metabolic pathways and intestinal efflux transporter implemented in PhysPK biosimulation software. Wednesday 15:10-16:40 |
| III-03 François Riglet Bayesian individual dynamic predictions of biomarkers and risk of event in joint modelling (with uncertainty): a comparison between Stan, Monolix and NONMEM Thursday 09:55-11:20 |
| III-15 Jérémy Seurat Comparison of Phase I combination therapy designs by clinical trial simulations to evaluate early tumor shrinkage Thursday 09:55-11:20 |
| III-36 Hadi Taghvafard Modeling (a)symmetry of concentration-effect curves Thursday 09:55-11:20 |
| III-37 Hiroyuki Takita The dynamics of pharmacological effects aimed at gut wall: A framework for a nested-target-within-enterocyte (NTWE) model that accounts for turnover of target and cell Thursday 09:55-11:20 |
| III-40 David Ternant Revisiting target-mediated elimination of therapeutic antibodies: the irreversible binding approximation Thursday 09:55-11:20 |
| III-45 Carlos Traynor Towards personalised medicine in Non-Small Cell Lung Cancer: design of a forecasting model of disease-progression to overall survival. Thursday 09:55-11:20 |
| III-70 Sebastian Weber Qualifying drug dosing regimens in pediatrics using Gaussian Processes Thursday 09:55-11:20 |
| III-72 Gustaf Wellhagen Modelling UACR as a clinical endpoint Thursday 09:55-11:20 |
| IV-04 Ronan Duchesne Identifiability in nonlinear mixed effect models: the example of in vitro erythropoiesis Thursday 15:25-16:50 |
| IV-44 Guenter Heimann An Industry Perspective on Extrapolation in Pediatric Drug Development: A Quantitative Approach to Assess Similarity of Adult and Pediatric Efficacy. Thursday 15:25-16:50 |
| IV-60 Itziar Irurzun-Arana ACESO (A Cancer Evolution Simulation Optimizer) Thursday 15:25-16:50 |
| IV-64 Jin Jin Model-informed artificial intelligence (AI) solution enabling real-time predictions: towards next generation modeling Thursday 15:25-16:50 |
| IV-72 Vangelis Karalis An In Vitro – In Vivo Simulation Methodology for Predicting the Outcome of Bioequivalence Studies Thursday 15:25-16:50 |
| IV-75 Adrien Tessier Use of mixture models in pharmacometric model-based analysis of confirmatory trials: part I - simulation study evaluating type I error and power of proof-of-concept trials Thursday 15:25-16:50 |
